Richmond Pharmacology is pleased to confirm our attendance at the EASL Congress 2025 in Amsterdam, one of the leading global events dedicated to liver research and hepatology, hosted by the European Association for the Study of the Liver.

This year’s congress will bring together experts from across the world to share the latest developments in liver disease research, clinical innovation, and therapeutic advances.

Representing Richmond Pharmacology:

  • Dr Jörg Täubel, Chief Executive Officer

Our team looks forward to engaging with clinical leaders, researchers, and industry partners to explore opportunities in:

  • Early-phase hepatology research
  • Rare and metabolic liver disease trials
  • Regulatory strategy and scientific advice

If you are attending EASL Congress and would like to learn how Richmond Pharmacology can support your liver-focused clinical development, we welcome you to connect with us during the event.

For meeting requests or collaboration enquiries:
info@richmondpharmacology.com

Learn more about the event:

Latest news

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event